Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. [More]
Inflammation associated with elevated glutamate in the brain could guide depression treatments

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine. [More]
MD Anderson signs collaborative research and development agreement with Enumeral

MD Anderson signs collaborative research and development agreement with Enumeral

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc. [More]
Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies. [More]
Finding may aid in the design of potential therapies for thyroid problems

Finding may aid in the design of potential therapies for thyroid problems

Thyroid disease affects about 12 percent of the U.S. population. While many people with thyroid disease don't even know they have it, an overactive or underactive thyroid can cause a slew of problems, including weight gain or loss, mood changes and infertility. In children, an underactive thyroid can be fatal, which is why they are tested for a deficiency at birth. [More]
F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed. [More]
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. [More]
Virginia Tech scientists find potential way to influence memory formation in the immune system

Virginia Tech scientists find potential way to influence memory formation in the immune system

Scientists at the Virginia Tech Carilion Research Institute have found a potential way to influence long-term memory formation in the immune system. The researchers published their results today in Nature Communications. [More]
Study shows clear role of bacteria in modulating immune function in the lungs

Study shows clear role of bacteria in modulating immune function in the lungs

Microbiota--the trillions of bacteria that co-exist in the body--regulate the ability of lung dendritic cells to generate immune responses, according to a study led by researchers from the Icahn School of Medicine at Mount Sinai, published online in the Journal of Experimental Medicine. [More]
Scripps biologist describes major advancement in flu vaccine research

Scripps biologist describes major advancement in flu vaccine research

Every fall, millions of people roll up their sleeves to get a flu shot. Up to 20 percent of the population gets the flu and more than 200,000 people are hospitalized with flu complications each year, according to the U.S. Centers for Disease Control and Prevention. While seasonal vaccines provide some protection, they are not always effective because the strains of influenza virus in the vaccine may not be well matched to the flu viruses circulating that year. So researchers are searching for a way to develop a more universal vaccine that would be effective against any variety of influenza. [More]
Fraunhofer scientists use antibodies to detect cancer cells in tissue samples

Fraunhofer scientists use antibodies to detect cancer cells in tissue samples

Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment. [More]
Myostatin antibody shows promise in treating age-related decline in muscle mass and power

Myostatin antibody shows promise in treating age-related decline in muscle mass and power

A proof-of-concept, phase 2 trial by an international research team has found promising results for a myostatin antibody in treating the decline in muscle mass and power associated with aging. [More]
Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it. [More]
Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies. [More]
Study shows why immune system fails to develop immunity during malaria infection

Study shows why immune system fails to develop immunity during malaria infection

Australian scientists have for the first time revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease. [More]
Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Lower levels of antibodies in saliva linked to increased risk of mortality

Lower levels of antibodies in saliva linked to increased risk of mortality

New research from the University of Birmingham has found that lower levels of antibodies in saliva are associated with of an elevated risk of mortality, and could be an early indicator of risk. [More]
Single VRC01 antibody infusion could suppress HIV level in people not taking ART

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today. [More]
Advertisement
Advertisement